In a landmark study published in The New England Journal of Medicine, researchers have confirmed that semaglutide, a widely used GLP-1 receptor agonist, significantly reduces the risk of major kidney disease events in people with type 2 diabetes and chronic kidney disease (CKD). This finding addresses a critical gap in understanding the drug's effects beyond blood sugar control and weight loss.

The double-blind, randomized trial involved 3,533 participants with both type 2 diabetes and pre-existing CKD. Patients were given either a weekly 1.0 mg subcutaneous injection of semaglutide or a placebo. The study was designed to track the progression to kidney failure, a substantial loss of kidney function (eGFR), or death from kidney-related or cardiovascular causes.

The results were so compelling that the trial was stopped early. The semaglutide group experienced a 24% lower risk of major kidney disease events compared to the placebo group. Key outcomes included:

A slower rate of decline in kidney function (eGFR) over time.
Fewer serious adverse events compared to placebo.
An estimated 20 people would need to be treated for about 3 years to prevent one major kidney disease event.

The conclusion is clear: for adults with type 2 diabetes and chronic kidney disease, semaglutide is a powerful tool for preserving kidney function and reducing the risk of both clinically important kidney outcomes and death from cardiovascular causes. This solidifies its role as a vital organ-protective therapy in this high-risk population.

Want to dive deeper into the data that's changing the standard of care for diabetic kidney disease? Read the full publication here.

Semaglutide Shows Major Kidney Protection in Landmark Diabetes Trial